About the MOTION Study

An investigational drug is being tested to see if it can shrink and manage TGCT patients’ tumors and symptoms in a clinical research study called the MOTION study.

The MOTION study is a phase 3 study with the goal of evaluating how the investigational drug reduces the tumor’s size and improves range of motion, physical stiffness, pain level, and quality of life. Some participants might receive placebo before receiving the investigational drug.

Who may be eligible?

Participants in the study must meet the following criteria*:

  • Men and women 18 years of age or older
  • Have a confirmed diagnosis of TGCT / PVNS, currently experiencing stiffness or pain
  • Surgery is no longer an option at this time and/or complications with surgery are expected
  • Be able to complete regular digital questionnaires to monitor their experience

*Additional eligibility criteria will apply.

Investigational Treatment: Vimseltinib (also known as DCC-3014)

  • Oral capsule taken twice a week
  • Designed to block the recruitment of inflammatory cells to the tumor (called an inhibitor), thereby blocking the tumor growth

Study Overview:

Study Overview:

Study participants will receive free of charge:
  • The investigational treatment or placebo
  • Study-related monitoring and care
  • Reimbursement for your travel expenses to and from the clinic or travel booking may be provided. (Check with your clinic site for more information about process and reimbursement limits.)